NewAmsterdam Pharma Company Earnings Call Transcripts
Fiscal Year 2026
-
Recent phase III data show strong LDL and MACE benefits, with additional advantages in diabetes and Alzheimer's biomarkers. U.S. and E.U. launches are on track, supported by robust financials and expanded leadership. Market opportunity is growing with new guidelines and broad clinical differentiation.
-
Obicetrapib has shown strong LDL and Lp(a) lowering in phase III trials, with European approval and major outcome data expected this year. Commercial prospects are robust, with label expansion in diabetes and Alzheimer's prevention studies underway, and significant differentiation from competitors.
-
Obicetrapib has shown robust LDL and Lp(a) lowering, strong tolerability, and a 21% MACE reduction in Phase III trials. Commercial launch in Europe is planned for late 2024, with PREVAIL outcomes data expected to drive U.S. uptake. Alzheimer's prevention and diabetes risk reduction are key differentiators.
-
PREVAIL and BROADWAY studies show aligned event rates, supporting confidence in outcomes. Obicetrapib stands out for its broad efficacy, safety, and convenience, with regulatory milestones expected in Europe and the U.S. this year. Commercial strategy targets a large, underserved population.
Fiscal Year 2025
-
Record attendance marked the 37th annual conference, with major updates on cardiovascular trials and regulatory progress. PREVAIL CVOT and other key studies are on track for 2026, while commercial strategies focus on maximizing launch impact and product differentiation.
-
Obicetrapib demonstrated strong efficacy in lowering LDL and Lp(a), reducing diabetes risk, and showing Alzheimer's biomarker benefits, with robust phase 3 and ongoing PREVAIL studies supporting regulatory and commercial plans. Market positioning is strengthened by broad medical support, a major European partnership, and a focus on payer value.
-
Three positive phase III studies support regulatory filings in Europe, with U.S. launch dependent on PREVAIL outcomes. Obicetrapib is positioned as a differentiated CETP inhibitor targeting broad patient populations, with a focus on payer access and a strong safety profile. Market opportunity is estimated above $5 billion, with plans for further Alzheimer’s research.
-
Obicetrapib is advancing toward a 2024 European launch, with the pivotal PREVAIL CVOT trial expected to deliver key data by late 2026 or early 2027. The drug differentiates itself through broad metabolic benefits, high goal attainment, and a strong IP position, while the expanding market offers room for multiple oral therapies.
-
Recent clinical data support broader LDL lowering and expanded treatment populations, with PREVAIL and BROADWAY trials showing strong efficacy and additional benefits. Obicetrapib is positioned for significant commercial opportunity and further development in Alzheimer's, with regulatory and launch milestones on track.
-
Recent clinical data support aggressive LDL lowering for a broader high-risk population, with guidelines expected to shift and the market for lipid therapies expanding. Obicetrapib is positioned for strong uptake due to its added benefits and ease of use, with key trial readouts and regulatory milestones anticipated through 2027.
-
PREVAIL, a large outcomes trial, is fully enrolled and on track, aiming to confirm the 21% MACE reduction seen in prior studies. Regulatory filings are progressing in Europe and the U.S., with commercial launch planned alongside outcomes data. Obicetrapib differentiates itself through efficacy, safety, and potential benefits in Alzheimer’s biomarkers.
-
The company expects EU approval and launch of its LDL-lowering therapy within 12 months, with strong efficacy in LDL and Lp(a) reduction and additional benefits for diabetes and Alzheimer's risk. PREVAIL outcome study is on track, supporting a broad US label and global market potential exceeding $8B.
-
Obicetrapib’s regulatory and clinical progress is advancing globally, with a strong focus on outcome-driven approvals and combination therapies. The drug’s robust efficacy in lowering LDL, Lp(a), and Alzheimer’s biomarkers, along with a favorable safety profile, positions it for significant market impact, especially as PREVAIL and RUBIN data mature.
-
Phase III data show robust LDL lowering, safety, and significant MACE reduction, with additional benefits in diabetes and Alzheimer's biomarkers. The drug is positioned for broad adoption, supported by strong clinical evidence, strategic partnerships, and a focus on combination therapies.
-
Obicetrapib demonstrated significant reduction in Alzheimer's biomarker PTL217, especially in APOE4 carriers, with favorable effects across multiple biomarkers and a strong safety profile. Experts highlighted its potential for early intervention and prevention, while regulatory discussions are ongoing to define the path forward.
-
Obicetrapib's phase 3 data show robust LDL-C, Lp(a), and small particle reductions, with a 21% MACE reduction and a 23% decrease in new-onset diabetes. PREVAIL is on track for 2026 completion with a four-point MACE endpoint, and commercial prospects are strong, with broad physician and payer support.
-
Aggressive LDL lowering targets and unmet needs are driving demand for new oral therapies. Obicetrapib shows strong efficacy, safety, and added benefits in phase III trials, with a robust financial position and launch preparations underway. Key data on Alzheimer's and cardiovascular outcomes will be presented soon.
-
Recent phase III successes and conference presentations highlight obicetrapib's strong efficacy in reducing LDL and Lp(a), with broad market potential across multiple cardiometabolic risk groups. Robust financials support ongoing trials and a planned U.S. launch around 2027.
-
Obicetrapib shows strong LDL and Lp(a) lowering, robust safety, and significant MACE reduction in phase 3 trials. Upcoming catalysts include PREVAIL outcome data, Alzheimer's and imaging trial results, and a strategic focus on broad patient applicability and payer access.
-
Obicetrapib demonstrated robust LDL and Lp(a) lowering, strong safety, and a 21% MACE reduction in phase III trials. Regulatory filings are planned for Europe in H2 2024 and the U.S. in H1 2026, with major data readouts and ongoing studies supporting broad market potential.
-
Obicetrapib, a CETP inhibitor, has shown strong efficacy and safety in phase III trials, with significant LDL and Lp(a) lowering and MACE reduction. Regulatory filings and major data releases are planned for 2024, with a commercial launch targeted for 2027 and robust pre-launch activities underway.
-
Obicetrapib showed strong efficacy and safety in three Phase 3 trials, with significant LDL and Lp(a) lowering, robust MACE reduction, and a unique safety profile. Regulatory filings are planned for Europe in 2024 and the U.S. post-PREVAIL data, with multiple data releases and a strong commercial launch strategy ahead.
-
Obicetrapib demonstrated strong efficacy and safety in Phase III trials, with significant LDL and Lp(a) reductions and a 21% MACE risk reduction. Regulatory filings are planned for Europe in 2024, with a U.S. launch aligned to outcomes data for maximum impact.
Fiscal Year 2024
-
Obicetrapib demonstrated robust LDL-C lowering and a 21% reduction in MACE at one year in the BROADWAY phase 3 trial, with a favorable safety profile and additional benefits on glycemic control and renal function. Regulatory filings are planned globally, with high confidence in the ongoing PREVAIL outcomes trial.
-
Obicetrapib demonstrates robust LDL and Lp(a) lowering with strong safety in phase 3 trials, including the recent TANDEM study. Upcoming BROADWAY and PREVAIL trials aim to confirm efficacy, safety, and potential cardiovascular and Alzheimer's benefits.
-
The phase III TANDEM trial showed the fixed-dose combination of obicetrapib and ezetimibe reduced LDL-C by about 50% and Lp(a) by 63%, with over 70% of patients reaching stringent LDL-C targets. The combination demonstrated a synergistic effect, a strong safety profile, and supports global regulatory filings.
-
Obicetrapib, a potent oral CETP inhibitor, shows strong LDL and Lp(a) lowering with excellent safety and is advancing through pivotal phase 3 trials. Upcoming BROADWAY and TANDEM results will inform regulatory filings, while PREVAIL aims to confirm cardiovascular outcomes.
-
The Phase III BROOKLYN trial showed that obicetrapib significantly reduced LDL-C by over 40% at one year in high-risk HeFH patients already on intensive lipid-lowering therapy, with a safety profile comparable to placebo. These results support its potential for broad use and regulatory approval, with further data from ongoing trials expected soon.
-
Obicetrapib, a potent CETP inhibitor, is advancing through pivotal Phase III trials with strong LDL and Lp(a) lowering, a favorable safety profile, and potential diabetes prevention benefits. Regulatory and market tailwinds, plus a robust commercial strategy, position it for broad impact.
-
Obicetrapib, a CETP inhibitor, is advancing through four phase III trials with two major data readouts expected in late 2024. The PREVAIL CVOT, now fully enrolled, targets a late 2026 readout. Strong financials support a strategy to launch with outcomes data in early 2027.